Applied Genetic Technologies Corporation (AGTC): Price and Financial Metrics

Applied Genetic Technologies Corporation (AGTC): $0.78

0.01 (+1.31%)

POWR Rating

Component Grades













Add AGTC to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where AGTC ranks best; there it ranks ahead of 82.76% of US stocks.
  • The strongest trend for AGTC is in Growth, which has been heading down over the past 179 days.
  • AGTC ranks lowest in Stability; there it ranks in the 9th percentile.

AGTC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AGTC is 0.01 -- better than merely 6.95% of US stocks.
  • With a price/sales ratio of 96.14, Applied Genetic Technologies Corp has a higher such ratio than 97.56% of stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AGTC comes in at -166.21% -- higher than that of only 2.01% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Applied Genetic Technologies Corp, a group of peers worth examining would be ARAV, SYBX, ALT, CBIO, and VBLT.
  • Visit AGTC's SEC page to see the company's official filings. To visit the company's web site, go to

AGTC Valuation Summary

  • In comparison to the median Healthcare stock, AGTC's price/sales ratio is NA% NA, now standing at NA.
  • Over the past 90 months, AGTC's price/sales ratio has gone NA NA.
  • AGTC's price/sales ratio has moved NA NA over the prior 90 months.

Below are key valuation metrics over time for AGTC.

Stock Date P/S P/B P/E EV/EBIT
AGTC 2021-08-31 NA 1.6 -2.5 -1.3
AGTC 2021-08-30 NA 1.6 -2.5 -1.3
AGTC 2021-08-27 NA 1.6 -2.6 -1.4
AGTC 2021-08-26 NA 1.6 -2.5 -1.3
AGTC 2021-08-25 NA 1.6 -2.5 -1.3
AGTC 2021-08-24 NA 1.6 -2.5 -1.3

AGTC Growth Metrics

    The 2 year price growth rate now stands at -7.42%.
  • The 2 year cash and equivalents growth rate now stands at 22.8%.
  • Its 2 year revenue growth rate is now at -89.46%.
Over the past 70 months, AGTC's revenue has gone down $35,461,000.

The table below shows AGTC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.5 -58.358 -63.25
2021-09-30 0.5 -54.192 -59.568
2021-06-30 0.5 -51.173 -57.829
2021-03-31 0 -51.504 -60.196
2020-12-31 0 -48.892 -56.534
2020-09-30 2.453 -43.822 -49.695

AGTC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AGTC has a Quality Grade of D, ranking ahead of 17.04% of graded US stocks.
  • AGTC's asset turnover comes in at 0.005 -- ranking 411th of 682 Pharmaceutical Products stocks.
  • HSTO, PLXP, and ABBV are the stocks whose asset turnover ratios are most correlated with AGTC.

The table below shows AGTC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 1 -1.382
2021-03-31 0.000 NA -1.146
2020-12-31 0.000 NA -1.079
2020-09-30 0.026 1 -0.945
2020-06-30 0.026 1 -0.842
2020-03-31 0.031 1 -0.796

AGTC Price Target

For more insight on analysts targets of AGTC, see our AGTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.78 Average Broker Recommendation 1.33 (Strong Buy)

AGTC Stock Price Chart Interactive Chart >

Price chart for AGTC

AGTC Price/Volume Stats

Current price $0.78 52-week high $4.15
Prev. close $0.77 52-week low $0.58
Day low $0.77 Volume 139,700
Day high $0.79 Avg. volume 517,114
50-day MA $0.85 Dividend yield N/A
200-day MA $1.79 Market Cap 39.58M

Applied Genetic Technologies Corporation (AGTC) Company Bio

Applied Genetic Technologies is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed for patients with severe diseases in ophthalmology. The company was founded in 1999 and is based in Alachua, Florida.

AGTC Latest News Stream

Event/Time News Detail
Loading, please wait...

AGTC Latest Social Stream

Loading social stream, please wait...

View Full AGTC Social Stream

Latest AGTC News From Around the Web

Below are the latest news stories about Applied Genetic Technologies Corp that investors may wish to consider to help them evaluate AGTC as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Henry Schein (HSIC) and Applied Genetic Technologies (AGTC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cytokinetics (CYTK – Research Report), Henry Schein (HSIC – Research Report) and Applied Genetic Technologies (AGTC – Research Report). Cytokinetics (CYTK) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics today and set a price target of $69.00. The company's shares closed last Tuesday at $39.94. According to TipRanks.

Christine Brown on TipRanks | February 15, 2022

Applied Genetic Technologies'' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 14, 2022

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on in

Yahoo | February 14, 2022

Applied Genetic Q2 2022 Earnings Preview

Applied Genetic Technologies (NASDAQ:AGTC) is scheduled to announce Q2 earnings results on Monday, Feb. 14, before market open.The consensus EPS Estimate is -$0.39.

Seeking Alpha | February 11, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO) and Applied Genetic Technologies (AGTC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sangamo Biosciences (SGMO – Research Report) and Applied Genetic Technologies (AGTC – Research Report). Sangamo Biosciences (SGMO) In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences, with a price target of $10.00. The company's shares closed last Tuesday at $5.61, close to its 52-week low of $5.32. According to TipRanks.

Catie Powers on TipRanks | February 8, 2022

Read More 'AGTC' Stories Here

AGTC Price Returns

1-mo -13.27%
3-mo -28.44%
6-mo -56.91%
1-year N/A
3-year -79.37%
5-year -84.55%
YTD -58.95%
2021 -53.55%
2020 -9.51%
2019 81.53%
2018 -30.83%
2017 -61.50%

Continue Researching AGTC

Want to see what other sources are saying about Applied Genetic Technologies Corp's financials and stock price? Try the links below:

Applied Genetic Technologies Corp (AGTC) Stock Price | Nasdaq
Applied Genetic Technologies Corp (AGTC) Stock Quote, History and News - Yahoo Finance
Applied Genetic Technologies Corp (AGTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4741 seconds.